Donatella Amatore

Donatella Amatore

Auto-generated profile, based on publicly available information

Donatella Amatore

Istituto di Scienze Biomediche della Difesa

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in ChemMedChem
Verified
Journal Article
Open access
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
RERoberta Emmolo
Roberta Emmolo
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
DADonatella Amatore
Donatella Amatore
SMStefania Maloccu
Stefania Maloccu
Roberta CostiRoberta Costi
Roberta Costi
It has been more than four years since the first report of SARS‐CoV‐2, the virus responsible for the coronavirus disease 2019 (COVID‐19) pandemic, the scientific community is focused on vaccine development in an exceptionally rapid time frame, as well as the evaluation of a wide range of potential treatments in clinical trials, a few of which have also reached the market. However, these drugs are characterized by several limits (including low response to treatment in some patients, low effectiveness against the new variants, severe side effects, etc.), thus underscoring the need to speed up the research. Among potential antiviral targets, the SARS‐CoV‐2 nonstructural protein 13 (nsp13) is highly promising thanks to its pivotal role in viral replication. Pursuing the studies on the development of nsp13 inhibitors, herein, the design, synthesis, and biological evaluation of new SARS‐CoV‐2 nsp13 inhibitors are reported. In general, the newly designed dikehexenoic derivatives are proven active against both the enzymatic activities showing measurable IC50 under 30 μM concentration, while the diketobutanoic series shows less promising results. Moreover, the tested compounds are capable of blocking viral replication without exerting cytotoxicity. Docking studies predict their binding into an allosteric pocket within the RecA2 domain.

12 August 2025 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
AAAurora Albano
Aurora Albano
RERoberta Emmolo
Roberta Emmolo
RSRiccardo De Santis
Riccardo De Santis
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
Roberta CostiRoberta Costi
Roberta Costi
COVID-19 pandemic stimulated tremendous efforts to develop therapeutic strategies targeting SARS-CoV-2, leading to the evaluation of a wide range of potential treatments in clinical trials. However, effective therapeutics remain elusive when the development of new variants and the limits of antiviral drugs is considered. Therefore, the development of antiviral drugs against SARS-CoV-2 is of paramount importance. Among potential drug targets, the SARS-CoV-2 nsp13 is highly attractive thanks to its pivotal role in viral replication. Pursuing our studies on the development of nsp13 inhibitors, in this work we describe the design, synthesis, and biological evaluation of novel inhibitors targeting SARS-CoV-2 nsp13. The newly designed N-benzyl indole derivatives were active against both enzymatic activities showing measurable IC50 under 30 μM concentration, while N-alkyl derivatives showed less promising results. Interestingly, the tested compounds blocked viral replication with no cytotoxicity. Docking studies predicted their binding into an allosteric conserved site located in the RecA2 domain.

10 November 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
RSRiccardo De Santis
Riccardo De Santis
GGGiorgia Grilli
Giorgia Grilli
GFGiovanni Faggioni
Giovanni Faggioni
AAAnna Anselmo
Anna Anselmo
FMFilippo Molinari
Filippo Molinari
RDRaffaele D'Amelio
Raffaele D'Amelio
Background/Objectives: Routine smallpox vaccination ended after eradication, leaving uncertainty about the persistence of vaccinia virus (VACV)-neutralizing antibodies and their activity against the monkeypox virus (MPXV) responsible for the 2022 outbreak. We assessed both responses in an Italian serum-bank cohort. Methods: We analyzed sera collected in 2016–2022 from 287 individuals born in or before 1974, whose presumed vaccination status was inferred from birth year, and 100 individuals born in 1977–1982. Neutralization of VACV ACAM2000 and an Italian clade IIb MPXV isolate was measured using the 50% plaque reduction neutralization test (PRNT50). We compared paired titers and calculated the proportions with titers ≥1:20, a putative threshold for VACV applied to MPXV for homogeneity, lacking any specific information. Results: In the earlier birth cohort, VACV-neutralizing antibodies were detected at titers ≥1:10 in 207/287 samples (72.1%) and MPXV-neutralizing antibodies in 137/287 (47.7%). Titers ≥1:20 were found in 121/287 (42.16%; 95% CI 36.59–47.94) for VACV and 68/287 (23.69%; 95% CI 19.14–28.94) for MPXV. MPXV titers were lower than paired VACV titers (p < 0.0001), and titers against the two viruses were positively correlated (Spearman’s rs = 0.90, p < 0.0001). All 100 sera from the younger birth cohort were negative for both viruses. Conclusions: VACV-neutralizing antibodies remained detectable in many individuals from cohorts likely vaccinated in childhood, including some individuals presumed vaccinated more than 60 years ago. Cross-neutralization of MPXV was less frequent and weaker. Integrated prospective investigations combining functional serology with T-cell responses in representative populations might be helpful for preparedness in case of deliberate release of variola virus. Real-world vaccine effectiveness data are crucial for epidemic emergency management of mpox.